Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy

NCT00226408 is registered in ClinicalTrials.gov with Dermatologic Cooperative Oncology Group as lead sponsor.

NCT NCT00226408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00226408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy
Lead sponsor
Dermatologic Cooperative Oncology Group
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2003
Completion date
September 30, 2005
Enrollment
600
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant, interferon alpha, stage iii malignant melanoma, therapy